+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07579208

Phase 1 Trial Evaluating Engineered NK Cells with Dual CAR and Gene Editing Delivered Locally for Recurrent Glioblastoma

Led by M.D. Anderson Cancer Center · Updated on 2026-08-25

36

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the best way to deliver engineered natural killer NK cells to patients with recurrent glioblastoma, a type of brain cancer. This Phase 1 trial aims to compare how NK cells persist, their immune characteristics, and their anti-tumor effects after being given through three different methods directly into the tumor, into the brains ventricles, or into arteries. The study also assesses the safety of these delivery methods and measures clinical outcomes such as tumor response, progression-free survival, and overall survival. Participants receive specially engineered NK cells that carry dual chimeric antigen receptors targeting IL13Ra and EGFRvIII, secrete IL-21, and have deletions of TGF-BetaR2 and NR3C1 genes. The NK cells are administered via one of three routes intra-tumoral injection, intra-ventricular injection, or intra-arterial injection, delivered either through an Ommaya reservoir or intravenous methods depending on the intervention arm. The trial evaluates and compares the biological and clinical effects of these different administration routes. During the study, participants undergo brain MRIs within 30 days before NK cell infusion and are monitored for safety and adverse events for about one year. Researchers assess immune changes in the blood and cerebrospinal fluid, tumor response using standard neuro-oncology criteria, and overall clinical outcomes. Participants are followed long term to track persistence of NK cells and immune responses, with ongoing evaluation of adverse events and disease progression throughout the study period.

CONDITIONS

Brief Title

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

Research Team

C

Chibawanye Ene, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here